
Northwell's Dr. Stacey E. Rosen assumes American Heart Association presidency
As the president, Dr. Rosen, a practicing cardiologist for over 30 years, serves as the lead volunteer scientific and medical officer of the organization. She will use her presidency to continue to champion health and hope for everyone, everywhere.
'I am honored to have the opportunity to serve as the next volunteer president of the American Heart Association as this extraordinary organization begins its 101 st year of operation. My vision for this term is to build on the Association's incredible legacy with a focus on scientific discovery that improves the lives of all people, advancing systems of care and policy that are accessible and promoting healthy lifestyles to improve health outcomes,' said Dr. Rosen. 'Together, with the more than 35 million volunteers and supporters of the Association nationwide, and the organization's staff, we will continue to be a relentless force for a world of longer and healthier lives.'
As volunteer president of the American Heart Association, Dr. Rosen will share insights to help guide the strategic direction of various Association committees. She will serve as: chair of the Science Advisory & Coordinating Committee; and as a member of the Executive Committee, Governance Committee, Corporate Operations Coordinating Committee, Compensation, Benefits and Human Resources Committee, and International Committee.
'Northwell is immensely proud of Dr. Rosen's appointment as president of the American Heart Association. Her tireless dedication to women's heart health and decades of service make her the perfect advocate to lead this vital organization,' said Michael Dowling, president and CEO of Northwell Health. 'During her tenure, we know she'll continue to make an even more of a profound difference in the lives of countless individuals and families.'
As a passionate volunteer, she has offered her time, clinical expertise and advocacy to advance the mission of the Association. Dr. Rosen has served in leadership roles at the local, regional and national levels, including the National Board of Directors. With a career focused on the cardiovascular health of women, Dr. Rosen is engaged in the Association's Go Red for Women™ initiative. In 2018, Dr. Rosen received the American Heart Association's Women in Cardiology Mentoring Award; and in 2021, she received its Physician of the Year Award.
Dr. Rosen oversees Northwell's Katz Institute for Women's Health. Its mission is to improve the health of women throughout their lives, bridging the gap between wellness and personalized care delivery. With a dedicated focus on women, the Katz Institute offers a comprehensive approach and sets the standards for excellence in patient-centered women's healthcare. It also serves as a convener and amplifier for all of Northwell's women's health initiatives, including supporting sex- and gender-specific research, providing expert, coordinated clinical care, and educating the community on prevention and well-being.
She is a highly sought-after expert in cardiology and women's health, frequently recognized for her accomplishments. In 2025, she and her colleague, Jennifer H. Mieres, MD received the American Medical Women's Association (AMWA) Lila A. Wallis Women's Health Award. In 2024, she was named one of Modern Healthcare's 50 Most Influential Clinical Executives and one of Reuters Events' Trailblazing Women in Healthcare. The previous year, 2023, she received the WomenHeart Wenger Award for Excellence in Medical Advocacy. Dr. Rosen co-authored the book Heart Smarter for Women: Six Weeks to a Healthier Heart (2022) and co-produced the documentary Ms. Diagnosed, which premiered at the Cinequest film festival in 2020.
About Northwell Health
Northwell is the largest not-for-profit health system in the Northeast, serving residents of New York and Connecticut with 28 hospitals, more than 1,000 outpatient facilities, 22,000 nurses and over 20,000 physicians. Northwell cares for more than three million people annually in the New York metro area, including Long Island, the Hudson Valley, western Connecticut and beyond, thanks to philanthropic support from our communities. Northwell is New York State's largest private employer with over 104,000 employees – including members of Northwell Health Physician Partners and Nuvance Health Medical Practices – who are working to change health care for the better. Northwell is making breakthroughs in medicine at the Feinstein Institutes for Medical Research. Northwell is training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, X, Instagram and LinkedIn.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
2 hours ago
- Business Wire
CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the publication of the Kidney Allograft Outcomes AlloSure Registry (KOAR) study in the American Journal of Transplantation. The landmark prospective study demonstrates the clinical utility of AlloSure® donor-derived cell-free DNA (dd-cfDNA) in improving rejection detection and guiding biopsy decisions in kidney transplant recipients. The KOAR study enrolled 1,743 patients across 56 U.S. transplant centers to evaluate the clinical utility of a dd-cfDNA surveillance protocol based on the DART study, which prescribed seven tests in year one and four annually in years two and three. A total of 18,584 AlloSure tests were obtained from the overall cohort. 'The scale and clarity of KOAR make it a landmark,' said Daniel C. Brennan, MD, Professor of Medicine at Johns Hopkins, author of the publication, and the senior author of the primary DART publication. 'In fact, it shows that dd-cfDNA should be considered the first-line test even before DSA. It's arguably the most powerful biomarker we have in kidney transplantation today.' 'KOAR confirms that dd-cfDNA is a clinically actionable tool that enhances how we detect and manage rejection,' said Jonathan S. Bromberg, MD, PhD, Professor of Surgery at the University of Maryland, lead author of the publication, and a key author on the DART publications. 'Importantly, it helps clinicians tailor care based on risk.' Key findings include: Elevated AlloSure was associated with a 6-fold increase in rejection yield in surveillance biopsies (39% vs. 7%, p<0.001) and a 4-fold increase in for-cause biopsies (47% vs. 12%, p<0.001). AlloSure elevations were detectable up to four months before ABMR and one month before TCMR, supporting its role in early detection and longitudinal monitoring. In post-biopsy monitoring, AlloSure levels declined significantly following treatment, while serum creatinine remained unchanged, reinforcing AlloSure's role in assessing treatment response. The study also demonstrated that dd-cfDNA levels correlate with rejection severity, with higher levels associated with ABMR and mixed rejection, and lower levels linked to borderline or TCMR 1A. This stratification capability positions AlloSure as a critical tool for tailoring immunosuppression and biopsy decisions based on individual patient risk. 'The KOAR study provides compelling evidence that dd-cfDNA can optimize biopsy utilization and improve clinical decision-making in kidney transplant care,' said Robert Woodward, Chief Scientific Officer of CareDx. 'AlloSure empowers physicians to detect rejection earlier and intervene more precisely, to achieve the ultimate goal of improving long-term graft survival.' The full publication is available online at: About CareDx CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit Forward Looking Statements This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with AlloSure Kidney. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloSure Kidney; risks that the findings in the KAOR study supporting the data may be inaccurate, general economic and market factors; risks that the findings in the studies supporting the data may be inaccurate, general economic and market factors, and other risks discussed in CareDx's filings with the Securities and Exchange Commission (the 'SEC'), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


Business Wire
3 hours ago
- Business Wire
ASP Introduces BIOTRACE™ Instant Read Steam System, Delivering Sterility Assurance in Just Seven Seconds
IRVINE, Calif.--(BUSINESS WIRE)--Advanced Sterilization Products (ASP), a global leader in infection prevention and sterilization solutions, is announcing the launch of the BIOTRACE™ Instant Read Steam System, the fastest FDA-cleared steam biological indicator system available in the U.S. Designed with sterile processing departments (SPDs) in mind, the new system delivers a readout in just seven seconds, drastically reducing wait time, minimizing errors, and enhancing clinical workflow efficiency. Current standard biological indicator systems can take 20 minutes or longer to generate a readout. BIOTRACE Instant Read Steam System changes the paradigm by offering SPDs the ability to verify sterilization results nearly immediately, which allows for faster decision-making, improved throughput, and reduced operational strain. In a hospital environment where every minute counts and every load matters, this technology enables confident, real-time transitions from sterilization to documentation. 'The launch of BIOTRACE Instant Read Steam System represents a significant advancement in our ability to deliver fast, actionable sterility data to frontline staff,' said Dr. Ivan Salgo, Vice President and Chief Medical and Scientific Officer at ASP. 'By reducing the readout time to just seconds, we're addressing a long-standing bottleneck that often impacts both productivity and peace of mind. This system supports SPDs not only in meeting compliance standards, but in exceeding them, with confidence.' Developed with advanced fluorescence detection, BIOTRACE Instant Read Steam System streamlines routine monitoring of steam sterilization cycles without compromising accuracy. The compact reader accommodates two simultaneous test positions, records the last 50 results, and connects seamlessly to digital infrastructure via USB, Wi-Fi, or Bluetooth®. Integration with the BIOTRACE™ Assist App and SM Cloud™ Web Application enables secure cloud storage, enhanced traceability, and automated reporting for hospital instrument tracking systems including CensiTrac™ and other major ITS software solutions. 'ASP is proud to lead the charge in redefining sterility assurance,' said Chad Rohrer, Global President of ASP. 'This is a leap forward in our commitment to help hospitals do more with less, supporting frontline staff with technology that empowers their work. The introduction of BIOTRACE Instant Read Steam System reinforces our role as a trusted partner in innovation for infection prevention, while elevating the standards of care and operational excellence.' A recent usability study confirmed that throughput and staffing remain top concerns in SPDs nationwide. Respondents cited a strong willingness to invest in time-saving technology, recognizing the value of immediate sterilization verification in high-pressure clinical environments. Hospitals and health systems can request demos and evaluation kits by contacting their ASP representative. About Advanced Sterilization Products (ASP) Advanced Sterilization Products (ASP), a Fortive company, is a global leader in infection prevention dedicated to safeguarding patients during their most critical moments. With a proven history of pioneering low-temperature sterilization and sterility assurance solutions, ASP delivers innovative technologies designed to raise the standard of care across healthcare settings. From terminal sterilization with hydrogen peroxide gas plasma to advanced steam monitoring tools, ASP supports healthcare facilities worldwide in improving efficiency, compliance, and patient safety. For more information, visit Advanced Sterilization Products (ASP) and Censis Technologies are subsidiaries of Fortive Corporation. CensiTrac™ software is a product of Censis Technologies. DISCLOSURE: The third-party trademarks used herein are the properties of their respective owners.


Business Wire
6 hours ago
- Business Wire
Pleno Inc. Announces First Commercial Agreement with Slopes Bio, Inc.
SAN DIEGO--(BUSINESS WIRE)-- Pleno Inc., an early-stage biotechnology company developing innovative multi-omic solutions, and Slopes Bio, Inc., an innovative high-complexity accredited laboratory, today announced a comprehensive commercial agreement in biological target detection and personalized health. The agreement marks the official commercial launch of Pleno's RAPTOR™ instrument platform. This agreement with Slopes Bio helps bring to life our vision of AI-driven precision medicine at scale with RAPTOR. Share The two companies are collaborating closely on a pilot project to develop an extensible polygenic risk score panel for use in Slopes' laboratory with more than 400 patient samples processed. Clinical data demonstrated the improved accuracy, target plexity and economics of Pleno's proprietary Hypercoding™ technology when compared to existing solutions. A white paper with additional detail is to be published shortly. Under the terms of the agreement, Slopes Bio will purchase up to five RAPTOR instruments and corresponding consumables sufficient to process more than 100,000 samples annually. The first two instruments will be deployed in Slopes' Utah-based production lab beginning later this month. "This agreement with Slopes Bio helps bring to life our vision of AI-driven precision medicine at scale with RAPTOR," said Dr. Vik Vaz, CEO of Pleno. "An industry leader like Slopes Bio's deployment of multiple RAPTOR instruments in their production lab demonstrates both the commercial viability and the real-world scalability of our platform. Together, we're positioned to transform how the industry approaches high-throughput biological target detection." The finalized collaboration also extends beyond the current planned instrument deployment. Pleno and Slopes will jointly develop multiple high-sample-volume applications to meet increasing market demand for high plexity, efficient, scalable solutions in personalized health and wellness testing. "Pleno's RAPTOR technology aligns perfectly with our mission to empower health and wellness innovators with reliable, efficient laboratory services," said Justen Nadauld, CEO of Slopes Bio. "The performance improvements and cost efficiencies enabled by Hypercoding will allow us to scale our operations significantly while maintaining the quality standards our clients expect." The August 2025 deployment positions both companies to capitalize on the growing demand for high-throughput biological analysis in personalized medicine. About Pleno Inc. Pleno Inc. is a San Diego-based biotechnology company developing the RAPTOR™ multi-omic instrument platform to revolutionize biological target detection. Powered by proprietary Hypercoding™ technology, able to detect up to 10,000 targets per sample, RAPTOR simplifies complex multi-omic workflows and delivers unprecedented improvements in performance, cost, and scalability across applications including oncology, pharmacogenomics, genotyping, proteomics, and agrigenomics. For more information visit the website About Slopes Bio, Inc. Slopes Bio is a high-complexity, accredited laboratory that empowers health and wellness innovators with reliable, efficient, and actionable lab services. From custom assay development to end-to-end testing, kitting, and analytics, Slopes Bio brings personalized health solutions to life.